ATEC to Participate in Upcoming Investor Conferences

CARLSBAD, Calif.--(BUSINESS WIRE)-- Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that Pat Miles, Chairman and Chief Executive Officer, and Todd Koning, Chief Financial Officer, will participate in the following investor conferences:

• The 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 4:20 pm ET
• The 42nd Annual Cowen Healthcare Conference on March 7, 2022, at 2:50 pm ET
• The 17th Annual Canaccord Genuity Musculoskeletal Conference on March 22, 2022, at 1:00 pm CT

If available, a webcast of the conference presentations and archived recordings will be available in the Investor Relations Section of the Company’s website.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005272/en/

Investor/Media Contact:
Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
[email protected]

Company Contact:
J. Todd Koning
Chief Financial Officer
Alphatec Holdings, Inc.
[email protected]

Source: Alphatec Holdings, Inc.

You May Also Be Interested In

• Iceotope Wins Best HPC Cooling Innovation at the 2026 Nimbus Innovation Awards
• Prepayments (CK93) - Totalkredit A/S
• Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors